physicians in New Mexico notified the New Mexico Department of Health and Environment of 3 patients with marked eosinophilia and severe. incapacitating myalgia who had been taking the amino acid L-tryptophan (orally) and whose illness, after thorough clinical evaluation, seemed both unusual and obsc
Post-epidemic eosinophilia–myalgia syndrome associated with L-tryptophan
✍ Scribed by Jeffrey A. Allen; Alicia Peterson; Robert Sufit; Monique E. Hinchcliff; J. Matthew Mahoney; Tammara A. Wood; Frederick W. Miller; Michael L. Whitfield; John Varga
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 354 KB
- Volume
- 63
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The clinical constellation of leukocytosis, thrombocytosis, and low or absent stainable neutrophil alkaline phosphatase (NAP) is considered characteristic of chronic myelogenous leukemia (CML) [l]. CML with eosinophilic differentiation (eosinophilic leukemia) is well described [2], and leukemia and
Objective. To investigate the relationship between L-tryptophan (LT) ingestion and eosinophilic fasciitis (EF) occurring prior to the outbreak of eosinophiliamyalgia syndrome in 1989. ## Methods. Interviews and record reviews of 45 EF case-patients and 126 polymyositis patients (controls) diagnosed
## Abstract ## Objective To assess L‐tryptophan (LT) dose, age, sex, and immunogenetic markers as possible risk or protective factors for the development of LT‐associated eosinophilia–myalgia syndrome (EMS) and related clinical findings. ## Methods HLA–DRB1 and DQA1 allele typing and Gm/Km pheno